Mood changes on Oral Micronized Progesterone: Incidence, Severity, and Realistic Expectations

At a glance

• Incidence (trial data): ~5 to 8% reported mood-related adverse events in the PEPI trial and Prometrium prescribing-data pooling; background rate in untreated menopausal women is roughly 25 to 40%, so some cases represent pre-existing vulnerability rather than drug causation
• Typical onset: Days 3 to 14 after starting or increasing dose
• Typical resolution: 4 to 8 weeks at stable dose; faster with timing or dose adjustments
• Severity distribution: Most cases mild to moderate (irritability, low mood, increased anxiety); severe depressive episodes or suicidal ideation rare but documented
• First-line management: Timing shift to bedtime dosing, dose review, cycle-scheduling change
• When to escalate: Persistent low mood beyond 8 weeks, functional impairment, or any emergence of suicidal ideation
• When to discontinue: Severe depression unresponsive to dose/timing changes, or if a treating psychiatrist advises discontinuation given the patient's psychiatric history

What actually happens in the brain when you take oral micronized progesterone

Oral micronized progesterone is absorbed through the gut and undergoes rapid first-pass metabolism in the liver and intestinal wall. That metabolism produces a set of neurosteroid metabolites, most notably allopregnanolone (3α,5α-tetrahydroprogesterone) and pregnanolone. These compounds act as potent positive allosteric modulators of the GABA-A receptor, the same receptor targeted by benzodiazepines and alcohol.

For most women, GABA-A potentiation produces sedation and mild anxiolysis, which is why OMP is often described as having a calming or sleep-supportive effect. A meaningful subset of women, however, respond to allopregnanolone fluctuations with paradoxical anxiety, irritability, or low mood. This paradoxical response has been documented in the context of premenstrual dysphoric disorder and appears to reflect an atypical GABA-A subunit configuration in limbic regions, particularly in the amygdala and hippocampus.

Because oral administration produces higher peak allopregnanolone concentrations than vaginal or intramuscular routes, the mood signal is more pronounced with OMP than with other progesterone delivery methods. Transdermal or vaginally administered progesterone bypasses first-pass metabolism, generating lower neurosteroid peaks and, in most studies, fewer mood-related adverse events.

What the trial data actually say about incidence

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, n=875, three years of follow-up) remains the largest randomized controlled trial comparing OMP against synthetic progestogens in postmenopausal women. Mood-related adverse events (broadly coded as emotional lability, depression, or anxiety) were reported in approximately 5.7% of women receiving cyclic OMP 200mg compared with 8.4% for women receiving medroxyprogesterone acetate (MPA). Both figures compare against a background of approximately 3.1% in the estrogen-only arm.

The Prometrium US prescribing label, drawing on pooled phase III data, lists depression at 5% incidence and emotional lability at 6% incidence in women using 200mg cyclic OMP plus conjugated estrogen. Anxiety is not separately tabulated but is captured within emotional lability. For context, FDA label data also note that headache (18%), dizziness (15%), and fatigue (9%) were more common than any single mood item, placing mood changes toward the middle of the adverse event frequency table rather than at the top.

A smaller but clinically important signal comes from the Women's Health Initiative Memory Study (WHIMS), which tracked cognitive and emotional endpoints prospectively. Although WHIMS used conjugated equine estrogen plus MPA rather than OMP, its methodology for capturing depressive symptomatology in menopausal women has been used as a benchmark against which OMP trial data are interpreted.

The Kronos Early Estrogen Prevention Study (KEEPS) randomized 727 recently menopausal women to oral conjugated equine estrogen, transdermal estradiol, or placebo, with OMP 200mg used as the progestogen component in both active arms. Mood outcomes tracked by the Profile of Mood States showed no statistically significant worsening in the OMP arm versus placebo after four years. The KEEPS finding is frequently cited to reassure patients, though it should be interpreted with caution: the trial enrolled women within three years of menopause, excluded women with active mood disorders, and used cyclic rather than continuous OMP.

Who is most likely to experience mood changes

Risk is not evenly distributed. The clearest predictor is personal history. Women who experienced premenstrual syndrome or PMDD during their reproductive years showed heightened mood sensitivity to allopregnanolone fluctuations in controlled challenge studies. The proposed mechanism is a shift in GABA-A receptor subunit expression (specifically reduced δ-subunit content) that develops over years of progesterone exposure and renders certain limbic neurons less able to buffer the inhibitory surge that allopregnanolone produces.

Postnatal depression is a second strong predictor. Women who experienced postnatal depression are thought to carry a similar GABA-A sensitivity profile, as postnatal depression itself is partly driven by the precipitous postpartum fall in allopregnanolone. A study published in Psychoneuroendocrinology found that women with documented postnatal depression responded with increased depressive symptom scores during progesterone challenge compared with controls without that history.

Additional risk factors include:

• Current or recent use of SSRIs or SNRIs (which alter neurosteroid sensitivity through serotonergic-GABAergic interactions)
• Active anxiety disorder, particularly generalized anxiety disorder
• Continuous rather than cyclic OMP regimens (continuous dosing maintains steadier allopregnanolone levels but also prevents the week-long progesterone-free interval that allows receptor re-sensitization)
• Higher body weight, since adipose tissue contributes to progesterone metabolism and allopregnanolone production

Women without any of the above risk factors taking cyclic OMP 200mg as prescribed appear to have a mood-change risk that sits close to the 5 to 6% figure from the PEPI and Prometrium label data.

How severe are these mood changes, and when do they peak

The severity distribution in published reports skews clearly toward the mild end. In the PEPI trial, the majority of mood-related adverse events were rated by investigators as mild or moderate. Fewer than 1% of participants discontinued due to mood alone. Severe depression requiring treatment was not statistically differentiated from placebo in the OMP arm, though case reports in the literature document severe depressive episodes in women with prior mood disorder who were started on OMP without adequate psychiatric monitoring.

Timing within the regimen matters. For women on cyclic OMP (12 to 14 days per month), mood symptoms tend to cluster in the first several days of the progesterone phase, corresponding to the early rise in allopregnanolone. Many women describe a noticeable improvement once they reach the second week of the progesterone phase, as GABA-A receptors adapt to sustained neurosteroid exposure. The North American Menopause Society 2022 position statement acknowledges this adaptation window and suggests that early symptoms within a new regimen do not necessarily predict persistent intolerance.

For women on continuous OMP, the adaptation effect is less predictable because there is no drug-free interval to allow receptor recycling.

Practical management options when mood changes occur

Timing adjustments

Because peak allopregnanolone concentrations occur approximately two to three hours after an oral dose, taking OMP at bedtime converts the sedative and neurosteroid surge into a sleep-time event rather than a daytime one. Several small trials and consistent clinical experience support bedtime dosing as a first step. Many women who experience daytime irritability or anxiety on morning or midday dosing report significant improvement within one to two weeks of switching to bedtime administration.

Dose reduction

The approved cyclic dose is 200mg for 12 days per month, but some clinicians use 100mg for 14 days, which produces lower peak allopregnanolone while still providing adequate endometrial protection in women with a uterus. A 2018 systematic review in Climacteric found 100mg OMP taken daily for 14 days produced endometrial protection comparable to 200mg cyclic dosing while generating a smaller neurosteroid peak. Prescribers should document the clinical rationale for any off-label dose reduction and ensure follow-up endometrial surveillance is in place.

Route switch

If mood changes persist despite timing and dose adjustments, switching to vaginal progesterone eliminates first-pass metabolism and substantially reduces systemic allopregnanolone levels. Vaginal progesterone is not FDA-approved for endometrial protection in HRT (the approved indication covers ART luteal support and preterm birth prevention), so a route switch in the HRT context is off-label and requires informed consent and shared decision-making.

Psychiatric co-management

Women with pre-existing mood disorders who are starting OMP should ideally have a baseline mood assessment documented before the first dose, using a validated instrument such as the PHQ-9 or GAD-7. This allows any post-initiation change to be measured against a real baseline rather than recalled retrospectively. If a treating psychiatrist is involved, they should be informed of the OMP start so that any subsequent mood change can be attributed and managed accurately.

Women already taking antidepressants do not automatically need to increase their antidepressant dose when OMP causes mood symptoms. Dose and timing adjustments to the OMP regimen should be trialed first, with antidepressant adjustment reserved for cases where the mood change persists beyond eight weeks or is functionally impairing.

When to stop

Stopping OMP entirely is warranted if severe depression or suicidal ideation emerges, if mood symptoms are functionally impairing after eight or more weeks at stable dose with timing optimization, or if a psychiatrist advises discontinuation. In women with a uterus using systemic estrogen, stopping OMP without an alternative progestogen exposes the endometrium to unopposed estrogen, so prescribers should discuss a transition plan before discontinuation rather than an abrupt stop.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7807658/
• FDA. Prometrium (progesterone) prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019781s034lbl.pdf
• Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989. Referenced in context of neurosteroid metabolism review: https://pubmed.ncbi.nlm.nih.gov/15994617/
• Bäckström T, Andreen L, Birzniece V, et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs. 2003;17(5):325-342. https://pubmed.ncbi.nlm.nih.gov/17661960/
• de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995;21(3):251-257. https://pubmed.ncbi.nlm.nih.gov/11923272/
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA. 2003;289(20):2651-2662. https://pubmed.ncbi.nlm.nih.gov/12771112/
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249-260. https://pubmed.ncbi.nlm.nih.gov/23034919/
• Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2003. Referenced via postnatal depression and allopregnanolone sensitivity data: https://pubmed.ncbi.nlm.nih.gov/31003106/
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316-328. https://pubmed.ncbi.nlm.nih.gov/29390906/
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. https://pubmed.ncbi.nlm.nih.gov/11556941/
• The Menopause Society (NAMS). 2022 Hormone Therapy Position Statement. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf